Future Research Directions for Gemcitabine/Docetaxel Dr. Taylor's team noted that the effectiveness of gem/doce in BCG-unresponsive NMIBC has not yet been prospectively evaluated in clinical trials.

She received the first cycle of GT regimen palliative chemotherapy with gemcitabine 1g/m² (1.6g) on days 1 and 8, and docetaxel 75mg/m² (120mg) on day 1. She developed grade III leukopenia and urinary ...

What are the side effects of gemcitabine and nab-paclitaxel? Side effects can vary from person to person. They also depend on what other treatments you're having. When to contact your team Your doctor ...

Overview Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults. Commercial ...

The clinical evidence came from TOPAZ-1 which is an ongoing phase 3, double blind, randomised controlled trial. In this trial, durvalumab plus gemcitabine and cisplatin was compared with placebo plus ...

Prior to induction BCG, the gemcitabine-docetaxel group had a significantly higher proportion of patients with Ta/Tis (noninvasive) tumors compared with the BCG group (68.8% vs 52.2%), whereas the ...

WASHINGTON, DC—Sequential intravesical gemcitabine-docetaxel (Gem-Doce) for treatment-naïve high-risk nonmuscle-invasive bladder cancer (HR-NMIBC) achieves oncologic outcomes comparable to ...

Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to ...

Anticancer regimens with gemcitabine were adopted as initial treatment for these patiens. Three patients with NPC received gemcitabine combined with cisplatin (gemcitabine 1g/㎡ on day 1 and 8, ...

Artios announces initiation of phase 2 randomized trial for ATR Inhibitor ART0380 plus gemcitabine in patients with platinum resistant ovarian cancer. News release. February 10, 2023. Accessed ...